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Abstract
Many upper gastrointestinal (GI) endoscopies worldwide are performed for
inappropriate indications. This overuse of healthcare negatively affects healthcare
quality and puts pressure on endoscopy services. Dyspepsia is one of the most
common inappropriate indications for upper GI endoscopy as diagnostic yield is
low. Reasons for untimely referral are: unfamiliarity with dyspepsia guidelines,
uncertainty about etiology of symptoms, and therapy failure. Unfiltered open-
access referrals feed upper GI endoscopy overuse. This review highlights
strategies applied to diminish use of upper GI endoscopies for dyspepsia. First,
we describe the impact of active guideline implementation. We found improved
guideline adherence, but resistance was encountered in the process. Secondly, we
show several forms of clinical assessment. While algorithm use reduced upper GI
endoscopy volume, effects of referral assessment of individual patients were
minor. A third strategy proposed Helicobacter pylori test and treat for all dyspeptic
patients. Many upper GI endoscopies can be avoided using this strategy, but
outcomes may be prevalence dependent. Lastly, empirical treatment with Proton
pump inhibitors achieved symptom relief for dyspepsia and avoided upper GI
endoscopies in about two thirds of patients. Changing referral behavior is
complex as contributing factors are manifold. A collaboration of multiple
strategies is most likely to succeed.
Key words: Endoscopy; Dyspepsia; Medical Overuse; Guidelines; Proton Pump
Inhibitors; Helicobacter pylori
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Core tip: Strategies to halt overuse of upper gastrointestinal (GI) endoscopies are called
for. Dyspepsia represents the indication for the majority of inappropriate upper GI
endoscopies and provides a target for intervention. In this review, we describe four
strategies that can be used to reduce upper GI endoscopies. While all strategies
individually impact the number of performed endoscopies, a collaboration of improved
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guideline adherence, decision-making assistance, symptom management and
Helicobacter pylori screening is most likely to change referral practice.
Citation: de Jong JJ, Lantinga MA, Drenth JP. Prevention of overuse: A view on upper
gastrointestinal endoscopy. World J Gastroenterol 2019; 25(2): 178-189
URL: https://www.wjgnet.com/1007-9327/full/v25/i2/178.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i2.178
INTRODUCTION
Overuse of upper gastrointestinal (GI) endoscopy is emerging as a global concern[1-3].
It  is  estimated that  up to 56% of  diagnostic  upper GI endoscopy procedures are
inappropriate[4,5], i.e., not according to guidelines.
Inappropriate use is a major source of unnecessary costs, risk of complications, and
are associated with reduced diagnostic yield[6]. One of the most frequent indications
for upper GI endoscopy is dyspepsia but diagnostic yield is limited, especially for
patients  younger  than  60  years  of  age  and  for  those  patients  without  ‘alarm
symptoms’ such as unintended weight loss, hematemesis, melena, dysphagia, anemia
and persistent vomiting[4]. However, physicians still rely on upper GI endoscopy to
assign a suitable treatment for dyspeptic patients.  Patients hope that endoscopic
procedures  will  reveal  (or  exclude)  a  cause  for  their  symptoms.  Reassurance  of
negative endoscopy may have beneficial effects on symptoms in some, although no
long-term improvement in health related quality of life is seen[7].
The open-access system, which allows upper GI endoscopy referral without prior
specialist consultation, has fueled the increase in referrals. Despite curtailed criteria
for upper GI endoscopy referral by evidence-based guidelines, recent studies continue
to report overuse[8,9].
It is evident that mere publication of guidelines and highlighting overuse is not
sufficient to change referral practice.  In this review we discuss several strategies
applied to reduce the overuse of upper GI endoscopies for dyspepsia. We review
pitfalls and elements of success of these strategies in order to aid design of future
interventions.
Summary of clinical guidelines
Clinical guidelines are recommendations that assist clinicians in decision-making and
have the ability to improve quality of care[10]. Care given according to guidelines is
more efficient and consistent[11,12]. Several up-to-date practice guidelines recommend
diagnostic and therapeutic pathways for dyspepsia management. Widely used are the
American Society  for  Gastrointestinal  Endoscopy (ASGE)  guideline,  ‘the  role  of
endoscopy in dyspepsia’  (2015)[13];  two NICE guidelines,  ‘Dyspepsia and gastro-
esophageal reflux disease in adults’ (2015)[14] and ‘suspected cancer: recognition and
referral’ (2017)[15]; and the joint American College of Gastroenterology (ACG) and the
Canadian Association of Gastroenterology (CAG) guideline, ‘ACG and CAG clinical
guideline: management of dyspepsia’ (2017)[16].  Locally adapted versions of these
guidelines may be used per region.
While the ASGE advises upper GI endoscopy for all with new onset dyspepsia after
50  years  of  age  and  all  with  alarm  symptoms,  the  ACG&CAG  refrain  from
recommending endoscopic investigation for  those < 60 years of  age,  even in the
presence of alarm symptoms, so long as epigastric pain is the predominant symptom.
The NICE guideline recommends urgent endoscopy for dyspepsia for those under 55
years of age, only in the case of co-existent dysphagia. For patients over 55 years of
age, endoscopy is justified in the presence of weight loss and should be considered in
the case of  therapy resistance,  or anemia or raised platelet  count combined with
specific symptoms.
For  those  not  eligible  for  endoscopy  empirical  Proton  Pump  Inhibitors  (PPI)
treatment is advised as first choice over Histamine2-antagonists (H2-antagonists) in
all guidelines. Prokinetics or tricyclic antidepressants are second choice after acid-
suppressive therapy in the ACG&CAG guideline and are considered for endoscopy-
negative  dyspeptics  by  the  ASGE.  H.  pylori  testing  is  advised  dependent  on
prevalence (ASGE), when infection is suspected (NICE) or for all dyspeptic patients
(ACG&CAG).
In several areas with high gastric cancer incidence, for example Japan and Korea, a
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screening program for gastric cancer exists, which is outside the scope of the current
review.
GUIDELINE IMPLEMENTATION
Many, if not all, dyspepsia guidelines offer strict advice of when to use upper GI
endoscopies. Despite these recommendations, there is a global overuse of upper GI
endoscopies, which mirrors poor adherence to practice guidelines[1,3,4,17]. Reasons for
non-adherence are manifold and include a disconnect between guidelines and local
situation,  failure  to  reach  the  target  audience,  or  the  absence  of  a  specific
implementation strategy. Specifically, the overuse of upper GI endoscopies continues
because of a lack of a filter or specific feedback to the referring physicians.
This review highlights the measures and strategies that have been taken to improve
guideline adherence to reduce inappropriate upper GI endoscopy for dyspepsia.
We identified four studies that assessed the effect of guideline implementation to
reduce the volume of inappropriate referrals.  Details  of  the included studies are
summarized in Table 1.
An Italian field study examined the effects of implementation of an adapted version
of the ‘European Society of Primary Care Gastroenterology (ESPCG) dyspepsia and H.
pylori infection management guideline’[18]. This local version recommended prompt
upper GI endoscopy for uninvestigated dyspepsia for patients with alarm symptoms
or for patients > 45 years of age after repeat presentation. This contrasts with the
original ESPCG guideline which additionally recommends endoscopy for the latter
scenario at first presentation[19]. Implementation comprised three phases: selection of
the most suitable guideline by a dedicated group, adaptation based on prospectively
collected prescribing data, and assessment of prescribing behavior. Over six months,
2098 patients were treated for dyspepsia and 11.7% were ≤ 45 years of age. Referrals
for this group fell significantly with 63% at first and with 42% at repeat presentation.
There was no effect for the age group >45 years of age, explained by under-referral of
this group prior to guideline implementation.
A British group designed a different strategy to improve guideline adherence[20].
They took the following steps: hospital based (n = 359) and primary care based (n =
215) physicians received the ‘All Wales Dyspepsia Management guideline’. Recipients
were informed that specific feedback would be given on referrals outside the remit of
the guideline. Referrals were processed, irrespective of appropriateness. After five
months adherence rates to the dyspepsia guideline increased with 36% for primary
care physicians and that coincided with a (non-significant) 9% decrease in average
weekly referral rate. The opposite was true for hospital-based physicians. Adherence
did not change, but weekly referral rate fell by 31%.
Effects of passive guideline dissemination on the appropriateness of open-access
upper GI endoscopy referrals was compared with an educational program in a cluster
randomized  controlled  trial[21].  First,  the  ‘British  Society  of  Gastroenterology
dyspepsia management guideline’  was adapted to local  use and all  114 selected
primary care practices received a copy[22].  Subsequently,  an educational program
containing educational workshops, hand-outs and a reinforcement visit after three
months was compared with no education. After seven months, appropriateness of
upper GI endoscopy referrals was higher in the group that attended the education
workshop (73%)  compared  to  controls  (50%).  Interestingly,  participation  in  the
education program did not  influence the appropriateness of  referrals  within the
intervention group. This might be explained by the observation that appropriateness
was based on referral letters, which is less accurate than assessment of the indication
through interview or questionnaires.
In a pragmatic randomized controlled study, 47 primary care practices received a
summary of the ‘Maastricht consensus statement on management of H. pylori’[23,24]. In
addition, the intervention group received information actively promoting H. pylori
testing instead of upper GI endoscopy in patients < 55 years of age, serology service
was made available, and therapy was advised for every serology positive result. The
control group received information stating the lack of evidence for H. pylori testing for
dyspepsia.  After  1  year,  upper  GI  endoscopy referrals  had fallen  by  27% in  the
intervention group compared to 4% in the control group.
CLINICAL ASSESSMENT
Clinical assessment of upper GI endoscopy referrals by a gastroenterologist at the
outpatient clinic is time consuming. Since endoscopy is considered a safe procedure, it
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Table 1  Description of studies using a guideline implementation strategy to reduce upper gastrointestinal endoscopies
Study Country Sample Strategy Effect on UGIE referrals
Cardin et al[18], 2005 Italy 2098 patients Distribution of a locally
adapted international
guideline, changing referral
criteria.
Reduction: 63% (at first) and
42% (at repeat presentation)
Elwyn et al[20], 2007 United Kingdom 215 PCPh, 359 hospital
physicians
Feedback on referrals after
distribution of adapted
guideline.
Reduction: PCPh 9% (NS),
Hospital physicians 31%
Banait et al[21], 2003 United Kingdom 114 PCPr Educational program,
including workshops, hand-
outs, and reinforcement visit
(intervention), vs passive
guideline dissemination
(control)
Appropriateness of referrals:
Intervention 73%, Control
50%
Shaw et al[22], 2006 United Kingdom 47 PCPr Promotion of HP testing,
serology service, and
treatment advice
(intervention), vs reserved
approach to HP testing
Reduction: Intervention: 27%,
Control: 4%
PCPh: Primary care physicians; PCPr: Primary care practices; NS: Non-significant; HP: Helicobacter pylori; UGIE: Upper gastrointestinal endoscopy.
was deemed safe to short-circuit the gastroenterologist from the referral pathway[25,26].
Hence, the open-access system was launched and is by now adopted by many health
care organizations.
The concept of open-access referral was promoted for its potential to reduce costs
and waiting lists and improve early cancer detection rates. Indeed, open-access led to
a reduction of gastroenterologist  consultations,  but studies consistently failed to
detect improved cancer detection rates[27]. Many studies have documented that the
diagnostic  yield  of  open-access  upper  GI  endoscopies  is  low,  while  costs  have
increased[28,29]. In the absence of a filter, referrals through the open-access system are
liable to be performed for inappropriate reasons.
Adding an evaluation of all referrals to the system requires an additional step,
which abolishes the attractiveness of the refer-and-scope open-access system. On the
other hand, a low-cost filter, effectively reducing inappropriate referrals, may serve to
enhance rather  than obstruct  the  existing system.  Indeed,  censoring is  probably
needed to lower the high proportion of negative endoscopies[4].
There are fine examples of efforts to reduce the number of (inappropriate) upper GI
endoscopies using a method of clinical assessment.
Already  in  the  late  90s  of  the  last  century,  the  idea  arose  that  some  form  of
censoring of open-access referrals was necessary. Two one-stop dyspepsia clinics in
the  UK  assessed  the  appropriateness  of  referrals  through  history  and  physical
examination, for 12 and 22 mo[30,31]. Both clinics found a high level of agreement with
the original referral. Only 6%-14% of upper GI endoscopy referrals were cancelled
which is considerably lower than recent data shows.
An Italian study evaluated 5192 referral letters and ~10% of referrals were judged
as  inappropriate[32].  Interestingly,  this  study used a  biomarker  panel  in  selected
patients  that  indicates  the presence of  chronic  atrophic  gastritis.  A recent  meta-
analysis  of  27  studies  found  a  good  specificity  which  supports  the  use  of  this
biomarker panel[33]. An additional 0.7% of initially judged inappropriate referrals were
reselected for upper GI endoscopy because of presumed chronic atrophic gastritis. Six
percent of referrals were deemed inappropriate in view of the absence of a referral
letter.
A recent  study introduced a  ‘virtual  clinic’  to  decide on the best  pathway for
patients  referred  to  the  gastroenterology  outpatient  clinic  for  five  common
indications, including dyspepsia[34]. Based on age, symptoms and previous diagnostics
and treatment, the system decided on the need for (fast-track) upper GI endoscopy or
sent  the  primary  care  physician  an  advisory  letter.  While  impact  on  upper  GI
endoscopy volume was  not  described,  the  strategy  is  a  good example  of  a  self-
supporting clinical  assessment system. Of all  14245 patients  assessed,  32% were
managed without a face-to-face appointment.
A different approach of clinical  assessment is  ‘self-assessment’  through use of
decision  trees.  A  randomized  controlled  trial  demonstrated  the  use  of  such  an
algorithm  to  distinguish  patients  with  appropriate  indications  for  upper  GI
endoscopy according to locally adapted clinical guidelines, from those that would
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benefit from PPI treatment or H. pylori testing, based on presenting symptoms[35]. The
use of an algorithm resulted in a reduction of 35% of referrals for upper GI endoscopy
compared to usual care.
Details of the included studies are summarized in Table 2.
HELICOBACTER TEST AND TREAT
Dyspeptic symptoms such as postprandial fullness, early satiety and epigastric pain
or burning, could be attributed to Helicobacter pylori  (H. pylori) infection. H. Pylori
elicits inflammation of the gastric mucosa, and chronic gastritis[36-38]. Mucosal damage
reduces  ghrelin  levels,  which  leads  to  acid  hypersecretion  and  deterioration  of
gastrointestinal motility. Several studies have documented higher prevalences of H.
pylori  infection in patients with dyspepsia[39,40].  It is reasonable to postulate the H.
pylori eradication would result in improvement of symptoms in dyspepsia.
Disappointingly, meta-analyses of RCTs fail to show beneficial effects of H. pylori
eradication  in  dyspepsia,  although  the  risk  of  having  symptoms  after  12  mo
reduces[41,42]. Still, in view of the potential beneficial effects of H. pylori on dyspeptic
symptoms, the impact of test and treat strategies on the number of performed upper
GI endoscopies is of interest. Several studies have attempted to quantify this impact.
We found nine randomized controlled trials  (RCTs) reporting on reduction of
upper GI endoscopies through testing for and treatment of H. pylori. Details of the
included studies are summarized in Table 3.  Two came from Asia (China[43]  and
Malaysia [ 4 4 ]),  and  seven  were  performed  in  Western  Europe  (two  in  the
Netherlands[45,46],  four in the UK[47-50],  one in Denmark[51]).  Reductions of upper GI
endoscopies ranged from 68% to as high as 91.8%.
In six RCTs, primary care practitioners were free to refer test and treat patients for
upper  GI  endoscopy  after  randomization  if  symptoms  persisted [44-47,50,52].  A
considerable proportion (68%-94%) did not need additional upper GI endoscopy after
either  H. pylori  eradication or,  if  uninfected,  empirical  treatment  with PPIs,  H2-
antagonists, prokinetics or no treatment. Three RCTs used a time delimited period
after  which upper  GI  endoscopy was allowed,  if  symptoms persisted[43,49,51].  The
predefined period varied between 2-6 wk and the proportion of avoided endoscopies
was high (72%, 82% and 76%).
A Chinese  study  subjected  all  patients  to  upper  GI  endoscopy after  6  weeks,
irrespective of presence or absence of symptoms[43]. Four gastric erosions and three
duodenal  ulcers  were  the  only  tissue  abnormalities  found  in  a  cohort  of  78
asymptomatic, post-eradication patients.
Keeping many doctors from deciding against endoscopy for dyspeptic patients is a
fear of missing out upper gastrointestinal cancers. The prevalence of cancers in all
RCTs was extremely low. Across all studies, together representing 1531 patients, only
three (0.2%) cancers were found in test & treat patients. The majority (60%) of upper
GI endoscopies performed for persistent symptoms, did not reveal any abnormalities.
In two prospective studies, all dyspeptic patients without alarm symptoms referred
for upper GI endoscopy followed a test  and treat  strategy for  H. pylori[48,53].  This
avoided about 75% of upper GI endoscopies. A third prospective study similarly
tested all  dyspeptic  patients  for  the presence of  H. pylori  and treated those with
positive  tests[54].  Upper  GI  endoscopies  were  avoided  for  all  H.  pylori  negative,
asymptomatic  patients  (37%),  and all  H. pylori  positive  patients  or  symptomatic
patients were subjected to upper GI endoscopy. No upper gastrointestinal cancer was
found in the 588 patients included in the three studies.
EMPIRICAL TREATMENT
PPIs are being used to treat patients with dyspepsia, especially those with acid-related
symptoms[55].  Indeed,  a  meta-analysis  revealed that  PPIs  are more effective than
placebo to ameliorate symptoms in functional dyspepsia[56].
Prokinetic drugs might be helpful for patients with impaired gastric emptying[57].
Beneficial effects of prokinetics for dyspepsia were seen across studies, but a robust
relationship with specific dysmotility-like symptoms is absent[58].
Currently, PPIs are the therapeutic front runners in dyspepsia. Achieving symptom
relief is an important factor to battle inappropriate use of upper GI endoscopies, and
there is evidence that empirical treatment may be effective.
Three studies have examined the concept of  empirical  drug treatment against
prompt upper GI endoscopy. Details of the included studies are summarized in Table
4.
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Table 2  Description of studies using a clinical assessment strategy to reduce upper gastrointestinal endoscopies
Study Country Sample Strategy Effect on UGIE referrals
Rutter et al[30], 1998 United Kingdom 485 visits Patient assessment in one-
stop dyspepsia clinic
Cancelled: 6%
Mourad et al[31], 1998 United Kingdom 272 visits Patient assessment in one-
stop dyspepsia clinic
Cancelled: 14%
Baldasarre et al[32], 2016 Italy 5192 referrals Assessment of referral letters
and biomarker panel for
atrophic gastritis
Cancelled: 10%
Pelitari et al[33], 2017 United Kingdom 14,245 patients Virtual assessment system to
decide on best pathway for
dyspeptic patients
32% no face-to-face
appointment (not UGIE
specific)
Horowitz et al[34], 2007 Israel 138 patients Decision tree for symptom
management, based on
presenting symptoms
Reduction: 35%
UGIE: Upper gastrointestinal endoscopy.
One study treated 80 patients with empirical PPI for 2 wk and offered those with
persistent symptoms, subsequent H. pylori screening[59]. Upper GI endoscopies were
avoided in 69%. This result accords with a Danish study using a similar treatment
regime and prevented 63% (n = 184) of listed upper gastrointestinal endoscopies[60].
The Dutch study revisited their cohort after 1 year and found that 6.5% (n = 77) of
empirically treated patients were scoped[61]. One patient had developed gastric cancer
within the first year of follow-up.
Another  Danish  study  offered  206  patients  with  dyspepsia  4  weeks  of  H2-
antagonists as initial empirical treatment[62]. After one year, upper GI endoscopy was
avoided in only 34% of patients.
CONCLUSION
Four  strategies  reveal  four  important  targets  in  the  trajectory  of  dyspepsia
management that can be addressed to reduce inappropriate upper GI endoscopies
(see  Figure  1).  Whereas  guideline  implementation  strategies  focus  on  changing
physicians’ behavior, a second strategy intervenes further in the referral process and
assesses  correctness  of  made  referrals.  A  third  strategy  aims  at  detection  and
treatment of H. pylori, and lastly a strategy attempts to relieve symptoms through
empirical treatment.
Guideline implementation is a low-cost intervention using existing infrastructure
and  resources.  A  lasting  effect  can  be  expected,  due  to  its  educational  nature.
Adjusting  guidelines  to  local  situations  prior  to  implementation  may  be  time
consuming, but is of major importance for guideline acceptance[10].
Behavioral  change  is  the  basis  for  improvement  in  healthcare  quality,  but  its
delicate  nature  complicates  strategy  implementation.  Indeed,  in  the  studies
highlighted in this review, resistance was encountered when feedback on referrals
was given. Disagreement with guidelines and fear of losing clinical freedom were two
most frequently used arguments[20]. One study notes that 15% of physicians cited lack
of fit with clinical practice as a cause of non-adhere to guidelines[18]. And nearly 40%
of primary care physicians failed to attend educational workshops organized in the
context  of  guideline  implementation[21].  Despite  this  disappointing  data,  active
conveying of information about appropriate clinical behavior, including feedback,
educational meetings and reminders, increases guideline adherence and results in a
modest decline in upper GI endoscopy referrals.
Guideline implementation strategies are entirely directed at changing physicians’
behavior, which means that patient, institution, and finance-related factors are not
taken into account. Amongst others, these are factors which often play a role in the
level of guideline adherence.
All in all, strategies that actively implement guidelines improve appropriateness of
upper  GI  endoscopies  referrals  for  dyspepsia.  However,  this  strategy will  meet
resistance among referring physicians and, alone, is unlikely to be able to achieve the
desired  effect  on  referral  behavior.  Comprehensive,  inclusive,  and  multilevel
approaches will be needed to truly affect appropriateness of referrals.
Strategies involving clinical assessment ensure proper selection of patients with
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Table 3  Description of studies using a Helicobacter pylori test and treat strategy to reduce upper gastrointestinal endoscopies
Study Country Sample Strategy No endoscopy after HPtest and treat
Hu et al[43], 2006 China 161 patients UGIE vs HP testing (UBT) +
eradication (HP+) or
Cisapride (HP-).
Symptom relief: 44%.
Endoscopy for all after 6
weeks.
Mahadeva et al[44], 2008 Malaysia 432 patients UGIE vs HP testing (UBT) +
eradication (HP+) or
reassurance and/or empirical
treatment (HP-)
89%
Arents et al[45], 2003 Netherlands 270 patients UGIE vs HP testing (serology)
+ eradication (HP+) or
Cisapride (HP-)
68%
Laheij et al[46], 2004 Netherlands 199 patients UGIE vs omeprazole 2 wk
followed by UGIE (no
improvement) or HP serology
testing (relapse) + eradication
(HP+)
94%
Duggan et al[47], 2008 United Kingdom 584 patients UGIE vs HP test + endoscopy
(HP+) vs HP testing
(serology) + eradication
and/or endoscopy (HP+) or
Lanzoprazole (HP-).
73%
Heaney et al[49], 1999 United Kingdom 104 patients All received HP testing
(UBT). Randomization of
HP+ patients: UGIE or
eradication therapy.
73%
McColl et al[50], 2002 United Kingdom 708 patients UGIE vs HP testing (UBT) +
eradication (HP+).
92%
Lassen et al[51], 2000 Denmark 500 patients UGIE vs HP testing (UBT) +
eradication (HP+), PPI (HP-,
NSAID-, reflux+), or lifestyle
advice (HP-, NSAID-, reflux-)
60%
Fraser et al[48], 2003 New Zealand 173 patients All received UBT and
eradication if HP+
76%
Slade et al[53], 1999 United Kingdom 232 patients All received HP serology
testing + UGIE (HP
equivocal), eradication (HP+),
or usual care (HP-).
73%
Patel et al[54], 1995 United Kingdom 183 patients All received serology testing
+ UGIE for HP+, sinister
symptoms, or NSAID use.
37% (after HP-)
UGIE: Upper gastrointestinal endoscopy; HP: Helicobacter pylori; UBT: Urea breath test, NSAID: Nonsteroidal anti-inflammatory drugs.
indication for upper GI endoscopy. However, most clinical assessment strategies have
logistical challenges, as new steps are introduced within a well-established open-
access system, available in most healthcare settings. Also, extra costs and working
hours of a one-stop clinic or clinical assessment by an endoscopist neutralizes the
originally anticipated effects of an open-access system.
Low levels of inappropriateness were seen in studies that involved face-to-face
assessment of patients referred for upper GI endoscopy[30,31]. However, these studies
date from 1998, and different criteria for appropriateness of referrals were used at that
time. Also,  patients’  fear of serious disease or lack of confidence in conservative
treatment may have played a role[63]. In a face-to-face dyspepsia clinic, these factors
may not be changed, leading to upper GI endoscopy although not strictly appropriate.
Arguing  against  patients’  influence  is  the  equally  low  reduction  of  upper  GI
endoscopies found in the study evaluating referral letters[32].
Algorithms follow a more rigid approach, purely based on presence of variables,
such as symptoms. Algorithms are useful in decision-making and to guide clinicians
through the clutter of available evidence, as is the case for dyspepsia management.
Leaving out individual patient factors using an algorithm, resulted in a considerable
reduction of upper GI endoscopies compared to usual care[34]. However, the rigidity of
such aids is an important drawback as it negates sound clinical judgment.
The use of an extensive virtual assessor to select the right pathway for patients
effectively reduces the number of  referrals  to  outpatient  clinics[33].  Standardized
feedback was given,  aiding physicians in their  decision making,  and patients  in
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Table 4  Description of studies using an empirical treatment strategy to reduce upper gastrointestinal endoscopies
Study Country Sample Strategy UGIE avoided
Laheij et al[59], 1998 Netherlands 80 patients 2-wk PPI treatment. HP test
and treat for persistent
symptoms.
69%
Kjeldsen et al[60], 2007 Denmark 184 patients UGIE vs 2-wk PPI treatment
and HP testing + UGIE (no
improvement, recurrence at
age ≥ 45, or HP- and age < 45
yr), eradication (HP+ and age
< 45 yr), or PPI 2 additional
weeks (HP-, age < 45 yr, and
reflux+)
63%
Bytzet et al[62], 1994 Denmark 206 patients 4 weeks H2RA treatment 34%
UGIE: Upper Gastrointestinal endoscopy; PPI: Proton pump inhibitor; HP: Helicobacter pylori; H2RA: Histamine-2 receptor antagonists.
management of their disease. Key elements for success in this study were patient
involvement and the use of feedback in combination with the liberty of physicians to
overrule the system, if deemed appropriate.
Future studies should explore combinations of clinical assessment strategies. An
algorithm integrated in the referral process that gives feedback on, but does not reject,
referrals would be an effective form of clinical assessment, while maintaining patient
centered care.
H. pylori testing is a simple procedure that can easily be performed in primary care.
Cost effectiveness of H. pylori  test and treat is dependent on several local factors.
Overall, test and treat after failure of acid-suppression therapy is more cost effective
than prompt endoscopy, providing that H. pylori  prevalence is at least ≥10%, and
availability of endoscopy is good and costs > $200[64-66].
The prevalence of H. pylori is subject to considerable regional variation[67,68]. Highest
prevalence is generally found in Africa, Latin America and the Caribbean, and Asia.
Northern America features the lowest prevalence. However, even in low prevalence
countries,  the  bacteria  affects  a  substantial  population  and  should  always  be
considered when upper GI symptoms arise. Additionally, H. pylori is known to cause
non-cardia gastric cancer, and peptic ulcers, emphasizing the benefits of H. pylori
eradication[69,70].
Substantial numbers of upper GI endoscopies were avoided in trials that adopted a
test  and treat  strategy for  dyspepsia,  both  in  high and low H. pylori  prevalence
countries. Upper GI endoscopies performed for persistent symptoms usually resulted
in normal results and upper GI cancers were only incidentally found. This confirms
that with this strategy the probability of missing significant abnormalities is low.
Arguing against widespread use of a test and treat strategy is the disappointing
reduction of dyspeptic symptoms after eradication as reported by several clinical
trials[42]. H. pylori treatment, traditionally consisting of dual antibiotics with a PPI, may
result in novel on-treatment symptoms and carries the risk of antibiotic resistance[41]. It
is  advisable  to  take  these  factors  into  account  when  screening  for  H.  pylori  is
considered in patients at low risk of infection.
In view of the ability to reduce the volume of upper GI endoscopies, H. pylori test
and treat should be part of the diagnostic work-up of dyspepsia.
Most guidelines recommend empirical treatment with PPI or H2-antagonists. These
drugs are well-suited for primary care-based use, as they are safe, especially with
short-term use,  and costs  are  low[71,72].  Monitoring of  drug-use  duration is  often
integrated in primary care systems, preventing undesired prolonged use.
A pre-emptive treatment of  dyspepsia patients  avoids two-thirds of  upper GI
endoscopies[59,60]. Risk of missing malignancies is extremely low using this approach.
Which  strategy (PPI,  H2-antagonists)  avoids  most  upper  GI  endoscopies  is  still
unclear, as there have not been any head-to-head trials studying this outcome. A
superior effect of PPI over H2-antagonists for symptom reduction is consistently
shown.
Concerns have been raised about long-term safety of PPI use. However, these were
based  on  weak  evidence,  concerning  solely  observational  studies[73].  Robust,
randomized studies are needed to establish whether a causal  relationship exists.
Benefits of PPI treatment often outweigh the potential risk of adverse effects and
patients in need of acid-suppressive therapy should not be denied treatment. As with
any other drug, PPIs should be prescribed in the lowest possible dose for the shortest
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Figure 1
Figure 1  Model of four strategies applied to reduce overuse of upper gastrointestinal endoscopies, with key
elements per strategy and target audience (A); and benefits and pitfalls encountered per strategy to reduce
overuse of upper gastrointestinal endoscopies (B). PPI: Proton pump inhibitor; H2-antagonist: Histamine H2-
receptor antagonist.
possible  time.  Frequent  re-evaluation  of  the  appropriateness  of  use  and,  if  not
appropriate,  careful  stepwise  discontinuation  to  prevent  a  rebound  effect  is
paramount.
Empirical treatment of uninvestigated dyspepsia has been feared to ‘mask’ gastric
cancer[74]. Based on the declining incidence of gastric cancer in the Western world it is
unlikely that this is the case in low to moderate (e.g.  < 15 per 100.000) prevalence
countries. In particular, when adequate H. pylori testing is performed, and risk factors
are observed.
Empirical treatment with PPI and H. pylori test and treat strategies greatly reduces
the need for upper GI endoscopy. Individual choices for a suitable drug may be made
and switched if the initial choice fails.
In  this  review  we  report  four  strategies  that  reduce  the  volume  of  upper  GI
endoscopies for dyspepsia.  Dyspepsia is  a multifactorial  disorder and requires a
matching multi-level approach. Therefore, no single best strategy is the panacea for all
dyspepsia patients. Each intervention has its benefits and drawbacks and the key to
success are multiple rather than individual strategies.
Current research
A  randomized  clinical  trial  (TRIODe)  is  currently  ongoing  that  compares  a
multifactorial strategy involving e-learning with upper GI endoscopy (www.Clinical-
Trials.gov NCT03205319). The aim of this pragmatic study is to reduce the volume of
upper GI endoscopies through a combination of increased patient and physician
awareness  and  lifestyle  interventions.  The  e-learning  is  a  home-based  tool  that
addresses the limited value of upper GI endoscopies for dyspepsia, explains etiology
of dyspepsia and guides patients through lifestyle interventions. We will enroll 119
patients from four district general hospitals in the Netherlands. With this trial, we aim
to provide a framework that can be used to improve appropriateness of upper GI
endoscopy use.
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